Paracetamol (Acetaminophen)

Product Story

Paracetamol (acetaminophen) was first synthesized in 1878 by American chemist Harmon Northrop Morse at Johns Hopkins University, though its clinical significance was not recognized at the time. The compound languished in obscurity until 1893, when German pharmacologist Joseph von Mering investigated it alongside phenacetin — a structurally related molecule. Von Mering mistakenly dismissed paracetamol as too toxic, recommending phenacetin instead, which became the dominant analgesic for the next 60 years.

The true mechanism of paracetamol was not elucidated until the 1970s. Unlike NSAIDs, paracetamol acts primarily as a central COX inhibitor, reducing prostaglandin synthesis in the brain and spinal cord while having negligible activity at peripheral inflammatory sites. It does not inhibit gastric prostaglandin production, which is why it avoids the gastrointestinal toxicity that limits chronic NSAID use. Recent research has also identified an indirect role in activating the endocannabinoid system, contributing to its analgesic effects.

Paracetamol's key advantage is its unmatched safety profile when dosed appropriately. At recommended therapeutic doses (maximum 4 g/day in adults), it has no adverse effects on the gastric mucosa, platelet function, or renal blood flow — unlike NSAIDs. This makes it the antipyretic and analgesic of choice for patients with gastric ulcers, bleeding disorders, and those on anticoagulant therapy. It is uniquely indicated across all age groups, from neonates to the elderly, and is the only analgesic recommended by WHO for fever following childhood vaccination.

As of mid-2026, the global paracetamol API market exceeds 200,000 metric tons annually, with China and India accounting for over 80% of global production. The API is a high-volume, cost-sensitive commodity, making supply chain reliability, batch-to-batch consistency, and competitive freight economics the defining differentiators between suppliers. KingWish supplies paracetamol API meeting USP, EP, CP, and CEP standards with the documentation packages required by pharmaceutical manufacturers in regulated markets.

Quality Specifications

Pharmaceutical Applications

• Analgesic: First-line for mild to moderate pain including headache, dental pain, osteoarthritis, and dysmenorrhea. Standard dose: 500-1000 mg every 4-6 hours.
• Antipyretic: Antipyretic of choice for fever management across all age groups. Preferred over ibuprofen in patients with gastric sensitivity or bleeding risk.
• Post-vaccination fever: WHO-recommended prophylactic agent for fever and local reactions following routine childhood immunizations.
• Combination formulations: Paired with opioids (codeine, tramadol) for moderate to severe pain, and with decongestants/antihistamines in cold and flu products.
• Post-operative pain: Integral component of multimodal analgesia regimens, reducing opioid requirements by 20-30% when used as scheduled background analgesia.